A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

NCT06897475 · Recruiting

Last updated 2026-05-28

This clinical trial is testing the safety and effects of the medication LY3457263 compared to a placebo in adults with type 2 diabetes who are already taking a stable dose of semaglutide or tirzepatide.

Status Recruiting Currently enrolling participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 240 people Planned (estimated).

Who can join Ages 18–75 · all sexes

Timeline Started 2025-03 · est. completion 2027-01

Where 60 sites · Canada, Germany, Poland, Puerto Rico, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT06897475 ↗

Description as written by the study sponsor.

The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.

Treatments tested

LY3457263 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Change from Baseline in Hemoglobin A1c (HbA1c)
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes
GLP-1 drugs	semaglutide, tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06897475 ↗